BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $20.80 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $20.80.

Several equities analysts have commented on the stock. Royal Bank Of Canada raised their price target on shares of BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Cantor Fitzgerald increased their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC grew its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $9.53 on Monday. The company’s 50-day simple moving average is $9.27 and its 200-day simple moving average is $8.62. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.22. The stock has a market capitalization of $2.42 billion, a PE ratio of -5.35 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same quarter last year, the firm posted $0.20 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, sell-side analysts predict that BioCryst Pharmaceuticals will post -2.58 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.